Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 26, 2022; 10(6): 1883-1888
Published online Feb 26, 2022. doi: 10.12998/wjcc.v10.i6.1883
Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: A case report
Bin-Bin Shan, Yuan Li, Chang Zhao, Xiao-Qin An, Quan-Mao Zhang
Bin-Bin Shan, Yuan Li, Chang Zhao, Xiao-Qin An, Department of Pneumology, Shanxi Tumor Hospital, Taiyuan 030000, Shanxi Province, China
Quan-Mao Zhang, Endoscopy Center, Shanxi Tumor Hospital, Taiyuan 030000, Shanxi Province, China
Author contributions: Shan BB, Zhang QM, and Li Y conceived and designed the study; Zhao C analyzed the data; An XQ contributed to literature review; Zhang QM wrote the manuscript and reviewed and edited the manuscript; Shan BB and Li Y contributed equally to this study; all authors read and approved the final manuscript.
Informed consent statement: Written informed consent was obtained from the patient for publication of the clinical data and any accompanying images. This is a retrospective case report and institutional approval was not needed.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Quan-Mao Zhang, BSc, Chief Physician, Endoscopy Center, Shanxi Tumor Hospital, No. 3 Zhigongxin Street, Xinghualing District, Taiyuan 030000, Shanxi Province, China. hdyunqi@yeah.net
Received: August 5, 2021
Peer-review started: August 5, 2021
First decision: November 6, 2021
Revised: November 12, 2021
Accepted: January 11, 2022
Article in press: January 11, 2022
Published online: February 26, 2022
Processing time: 202 Days and 6.6 Hours
Core Tip

Core Tip: We presented a case of non-small cell lung cancer carrying the rare EGFR exon 19 insertion mutation. The patient had a good and durable response to afatinib, which provided clinical evidence for the use of afatinib in these patients.